

The effects of a prebiotic supplement on exercise induced asthma and markers of airway inflammation

Submission date 04/01/2016	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 06/01/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 27/02/2018	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Asthma is a common long-term condition that affects approximately 235 million people worldwide. It can cause coughing, wheezing, tightness of the chest and breathlessness. It is caused by inflammation of the small tubes that carry air in and out of the lungs (the bronchi). When a sufferer comes across something that then irritates their lungs (a trigger), the airways narrow causing the symptoms of the disease. Common asthma triggers include allergies (to for example, house dust mites or animal fur) and viral infections. Exercise-induced asthma occurs when the airways narrow during and/or after exercise. It is referred to as exercise-induced bronchoconstriction (EIB). It is very common in asthma sufferers and sports men and women. Asthma can be well-controlled with treatments such as inhaled corticosteroids and short- and long-acting Beta2-agonists. However, these therapies do not cure the condition or prevent disease progression. Many patients also don't take the treatment as they should. Treatments that help prevent the inflammation of the bronchi and the immune response to triggers, without causing harmful side effects, would therefore be of benefit. There is evidence to suggest that the gut microbiota (trillions of live bacteria that live in the gut) has a substantial influence on the immune system and the allergic reaction. Prebiotics have been shown to increase the growth and/or activity of beneficial bacteria in the gut and thereby may protect against and reduce the severity of allergic, and airway inflammatory diseases. Prebiotic Bimuno-galactooligosaccharides (B-GOS) are especially potent in selectively increasing the growth and/or activity of bifidobacteria (a common beneficial bacteria found in the gut). The effects of B-GOS on asthma in humans, however, is not known. Therefore, the aim of this study was to see if prebiotic supplementation in adults with exercise-induced asthma would reduce the severity of bronchoconstriction (narrowing of the airways) and whether it also helps reduce inflammation of the airways.

Who can participate?

Adults either diagnosed with asthma, or known not to have asthma.

What does the study involve?

All participants (whether asthma sufferers or not) are randomly allocated into one of two

groups. Those in group 1 are given B-GOS to take every day for 3 weeks (21 days). Those in group 2 are given a placebo (a dummy pill) to take every day for three weeks. All participants then resume their normal diet for two weeks before taking the other treatment for an additional 21 days (this means that all participants eventually take both treatments). Each participant attends a laboratory for lung function tests and blood samples to test for evidence of airway inflammation before they start each treatment and then 21 days later (when that treatment ends).

What are the possible benefits and risks of participating?

Participants may benefit from gaining a greater understanding into managing and controlling their asthma and exercise induced asthma. Risks include some discomfort when taking blood samples, and some participants might find that the tests trigger off their asthma symptoms. All asthmatic participants will have their own clinically prescribed medication (β 2-agonist) for treating episodes of asthma and EIB.

Where is the study run from?

Nottingham Trent University (UK)

When is study starting and how long is it expected to run for?

December 2012 to March 2014.

Who is funding the study?

Nottingham Trent University (UK)

Who is the main contact?

Dr Neil Williams

Neil.Williams@ntu.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr Neil Williams

ORCID ID

<https://orcid.org/0000-0002-2607-4572>

Contact details

Nottingham Trent University

Department of Sport Science

School of Science and Technology

Clifton Campus

Nottingham

United Kingdom

NG118NS

+44 (0)115 8483325

neil.williams@ntu.ac.uk

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title

The effects of a prebiotic galactooligosaccharide mixture (B-GOS) on the severity of hyperpnea-induced bronchoconstriction and airway inflammation in adults with asthma

Study objectives

It is hypothesised that a prebiotic galacto-oligosaccharide mixture (B-GOS) will reduce the severity of hyperpnea-induced bronchoconstriction and airway inflammation in adults with asthma.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Nottingham Trent University Human Ethics Committee, 27/11/2012, ref: 229

Study design

Single centre randomised double-blind placebo-controlled cross-over controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Exercise induced asthma

Interventions

Participants were randomly assigned to receive 5.5 g.day of either galactooligosaccharide B-GOS (Bimuno) or placebo (maltodextrin) (Clasado Ltd, Milton Keynes, UK) for 3 weeks.

Participants then followed a 2 week washout period (normal diet) before commencing the alternative supplement for the remaining 3 weeks.

Intervention Type

Supplement

Primary outcome(s)

Pulmonary function data (forced expiratory volume in 1 second, forced vital capacity, and peak expiratory flow) at baseline and in response to the eucapnic voluntary hyperpnoea test (in both asthmatic and non-asthmatic groups).

Data was collected at day 0 and day 21.

Key secondary outcome(s)

1. Baseline and post eucapnic voluntary hyperpnoea (EVH) blood sampling for markers of airway inflammation (chemokines CCL11 and CCL17; tumour necrosis factor-alpha (TNF- α); c-reactive protein; and immunoglobulin E) – (collected in both asthmatic and non-asthmatic groups)
2. Fraction of exhaled nitric oxide (collected in asthmatic group only)

Serum chemokine and TNF- α levels were measured from blood samples taken at baseline and 15 min, 60 min and 24 h after EVH.

Data was collected at day 0 and day 21.

Completion date

03/03/2014

Eligibility

Key inclusion criteria

1. Body mass index (BMI) 20-25 KG.M-2
2. Physically active 3 or more times a week , with each exercise session lasting at least 45 min
3. Non-smoker
4. Non-vegetarian or vegan
5. Asthma sufferers must have own clinically prescribed medication
6. Asthma sufferers must have a GP diagnosis

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Predicted forced expiratory volume in 1 second (FEV1) less than 65%
2. Previously diagnosed with COPD, emphysema, chronic bronchitis or similar respiratory illness
3. Previously admitted to hospital for asthma or other breathing difficulties
4. Asthma exacerbation within the last month (Course of steroids, or hospital visit)
5. History of heart failure, pulmonary hypertension, embolism, or other pulmonary heart disease
6. History of recurrent chest infections
7. Smoker
8. Acute infection within the last four weeks
9. Major operation within the past four months
10. Have a history of taking ω -3 PUFA supplements or supplements with antioxidants above recommended intake, or consume more than three fatty fish meals per week
11. Take a daily dose of aspirin or other NSAIDs
12. Currently taking a daily dose of anti-histamine

13. Currently taking long term asthma maintenance medications – corticosteroids, and leukotriene modifiers that you could not refrain from taking for 4 days prior to laboratory session

Date of first enrolment

02/12/2012

Date of final enrolment

01/12/2013

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Nottingham Trent University

Nottingham

United Kingdom

NG11 8NS

Sponsor information

Organisation

Nottingham Trent University

ROR

<https://ror.org/04xyxjd90>

Funder(s)

Funder type

University/education

Funder Name

Nottingham Trent University

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Available on request